Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease

2007/12/05 by Elisa Fabbrini, B. Selma Mohammed, Faidon Magkos +4 · 30 citations
Medicine · Nursing · #Liver Disease Diagnosis and Treatment #Diabetes, Cardiovascular Risks, and Lipoproteins #Fatty Acid Research and Health

paper · pdf · doi:10.1053/j.gastro.2007.11.038

Citations

• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
• Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Cited by

• Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes
• Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
• Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
• Structure-Function of CD36 and Importance of Fatty Acid Signal Transduction in Fat Metabolism
• Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
• Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. [europepmc]
• Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. [europepmc]
• Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. [europepmc]
• Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. [europepmc]
• Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. [europepmc]
• Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. [europepmc]
• Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. [europepmc]
• Targeting inflammation in metabolic syndrome. [europepmc]
• The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. [europepmc]
• Therapies in non-alcoholic steatohepatitis (NASH). [europepmc]
• Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. [europepmc]
• A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. [europepmc]
• Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications. [europepmc]
• Triglyceride Metabolism in the Liver. [europepmc]
• Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. [europepmc]
• Metabolically healthy obesity: facts and fantasies. [europepmc]
• Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. [europepmc]
• Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. [europepmc]
• Dysregulated lipid metabolism links NAFLD to cardiovascular disease. [europepmc]
• Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. [europepmc]
• How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? [europepmc]
• Metabolic-associated fatty liver disease and lipoprotein metabolism. [europepmc]
• Role of Insulin Resistance in MAFLD. [europepmc]
• Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. [europepmc]
• Why does obesity cause diabetes? [europepmc]